This study reports the following: (1) frequency of TP53 comutation within each component of the European LeukemiaNet 2022 acute myeloid leukemia risk classification, (2) relevance of TP53 mutated variant allelic fraction <10%, (3) prognostic impact of −7, −5/del(5q), −17/abn(17p), complex karyotype/monosomal karyotype, or myelodysplasia-related gene mutations with/without mutated TP53.

Subjects:
Clinical Trials and Observations, Myeloid Neoplasia
1.
Arber
DA
,
Orazi
A
,
Hasserjian
RP
, et al.
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
.
Blood
.
2022
;
140
(
11
):
1200
-
1228
.
Google Scholar
Crossref
Search ADS
PubMed
 
2.
Rücker
FG
,
Schlenk
RF
,
Bullinger
L
, et al.
TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome
.
Blood
.
2012
;
119
(
9
):
2114
-
2121
.
Google Scholar
Crossref
Search ADS
PubMed
 
3.
Grob
T
,
Al Hinai
AS
,
Sanders
MA
, et al.
Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome
.
Blood
.
2022
;
139
(
15
):
2347
-
2354
.
Google Scholar
Crossref
Search ADS
PubMed
 
4.
Stengel
A
,
Haferlach
T
,
Baer
C
, et al.
Specific subtype distribution with impact on prognosis of TP53 single hit and double hit events in AML and MDS
.
Blood Adv
.
2023
;
7
(
13
):
2952
-
2956
.
Google Scholar
Crossref
Search ADS
PubMed
 
5.
Weinberg
OK
,
Siddon
A
,
Madanat
YF
, et al.
TP53 mutation defines a unique subgroup within complex karyotype de novo and therapy-related MDS/AML
.
Blood Adv
.
2022
;
6
(
9
):
2847
-
2853
.
Google Scholar
Crossref
Search ADS
PubMed
 
6.
Short
NJ
,
Montalban-Bravo
G
,
Hwang
H
, et al.
Prognostic and therapeutic impacts of mutant TP53 variant allelic frequency in newly diagnosed acute myeloid leukemia
.
Blood Adv
.
2020
;
4
(
22
):
5681
-
5689
.
Google Scholar
Crossref
Search ADS
PubMed
 
7.
Döhner
H
,
Wei
AH
,
Appelbaum
FR
, et al.
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
.
Blood
.
2022
;
140
(
12
):
1345
-
1377
.
Google Scholar
Crossref
Search ADS
PubMed
 
8.
Abbas
HA
,
Ayoub
E
,
Sun
H
, et al.
Clinical and molecular profiling of AML patients with chromosome 7 or 7q deletions in the context of TP53 alterations and venetoclax treatment
.
Leuk Lymphoma
.
2022
;
63
(
13
):
3105
-
3116
.
Google Scholar
Crossref
Search ADS
PubMed
 
© 2023 by The American Society of Hematology
2023
You do not currently have access to this content.
Sign in via your Institution